28.07.2011 • News

Ashland Q3 Profit Plunges On Raw Material Costs

Ashland Chairman and Chief Executive Officer James OBrien said: Our June... — Ashland Chairman and Chief Executive Officer James O'Brien said: "Our June quarter results were significantly affected by steep raw-material cost increases."

Specialty chemicals company Ashland reported Thursday its third-quarter preliminary results with net income of $87 million or $1.09 per share, lower than last year's $1.85 per share. Income from continuing operations was $69 million or $0.86 per share, compared to last year's $1.46 per share.
Adjusted earnings from continuing operations fell to $0.92 per share from $1.01 per share a year ago.

On average, nine analysts polled by Thomson Reuters expected earnings of $0.84 per share. Analysts' estimates typically exclude special items.
Ashland Chairman and Chief Executive Officer James O'Brien said, "Our June quarter results were significantly affected by steep raw-material cost increases."

However, sales increased 13% to $1.67 billion. Analysts expected sales of $1.65 billion.

Looking ahead, the company noted that its principal challenge in the near term continues to be recovery of raw-material cost increases.

Expert Insights

Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.